Coherent Slides 12% Post-Earnings as Analysts Rebase Targets

Coherent Corp. makes the optical components that move data inside hyperscale data centres, and this week those shares fell 12% to $207.49, the worst weekly performance among its closest peers and roughly 38% below where they traded a month ago.

The drop followed fiscal Q1 results that landed after the close on Friday 31 October. Earnings day itself brought an 11% decline to $210.32, erasing the 14% pre-earnings bounce that had formed through late October. Tuesday's 3.8% recovery is the first sustained positive session since, bringing the stock back to roughly $207. That still leaves Coherent trading at a steep discount to where the analyst community was pricing it even a few weeks ago. For context, the median one-week move across the eight closest correlated peers was around minus 0.2%. FN gained 5.9% on the week. GLW and KN were both close to flat. Coherent's loss was not a sector story; it was specific to the print.

Short interest has continued to drift lower since the results, now at 5.6% of free float on 8.9 million shares, down from above 11 million in mid-October. That unwind preceded earnings rather than following them, which matters: shorts who covered into the pre-results bounce and then saw the stock fall harder than anticipated have not yet visibly rebuilt. The borrow market is loose in the extreme, with availability at 2,621%, meaning there are roughly 26 shares available to borrow for every one currently lent out. The 52-week low for availability was 680%, so today's reading is well above that floor. Cost to borrow has drifted higher over the past month, up 29% to 0.53%, but in absolute terms that remains a negligible carry cost. The ORTEX short score has eased from around 38.7 on 22 October to 35.1 now, a mild directional softening that is consistent with shorts reducing rather than pressing. Options positioning is elevated in absolute terms: the put/call ratio is 1.58, above its 20-day average of 1.53, though only half a standard deviation above that mean. The 52-week high on the PCR is 1.72; the current reading is not at extremes, but it reflects a persistent preference for downside protection that has been a feature of this name for weeks.

The Street has been busy cutting targets. Morgan Stanley lowered its price objective to $325 from $375 on 30 October while holding its Equal-Weight rating, the clearest bellwether signal from the week. B. Riley trimmed to $262 from $297 the same day. Needham, which remains a buyer, cut to $380 from $420 on 27 October. TD Cowen went further in mid-October, dropping its target from $395 to $275 while keeping a Buy. The mean target across 17 Buy-rated analysts and 5 Hold-rated analysts now stands at $388, against a stock price of $207. That gap is wide enough to flag: the consensus implies roughly 87% upside from current levels, which either reflects genuine conviction in the multi-year InP ramp or targets that have not yet been fully rebased post-print. The divergence between the bull case, $10.6bn of modelled FY27 revenue against negative free cash flow of roughly $934m in the same year, and the bear case, $11.8bn of vendor commitments and an operating cash flow of only $79.5m in FY26 against capex of over $1bn, is the central debate the Street is working through. Factor scores are mixed: EPS momentum over 90 days ranks at the 74th percentile but EPS surprise is only in the 29th percentile, and the EV/EBIT factor ranks in the 18th percentile, reflecting the valuation stretch. The price-to-book has compressed sharply, down more than two turns over the past 30 days to 3.1x.

One feature on the register is worth flagging. BCPE Watson, which filed an activist Schedule 13D in November 2025 and has amended it five times since, last disclosed a stake above 5%. The most recent amendment was in February 2026 and carried no updated ownership figure. Per standard 13D/G disclosure rules, the stake is as last reported; a holder can drop below 5% without filing again. With the stock now 38% below its month-ago level, the activist angle is worth monitoring for any further disclosure.

Retail attention, as measured by Wikipedia page views and ORTEX stock page traffic, jumped sharply in late October, with a z-score of 3.5 against the company's own trailing 90-day history as of 31 October. That is an attention spike rather than a revenue indicator, but it suggests the post-earnings drop pulled in a significant wave of new viewers.

The next thing to watch is whether short sellers rebuild positions now that the earnings event has passed and the stock has reset to lower levels, and whether analysts who have not yet updated their targets following the Q1 report follow Morgan Stanley's lead in moving numbers closer to current market price.